KLB and metabolic disease: Beyond regulating metabolic disorders in T2D, FGF21 may also directly act on the heart to ameliorate DCM, as FGFR1 and KLB—the receptor and co-receptor mediating the biological functions of FGF21—are expressed in cardiac tissue [15,16,17,18]).